Skip to main content

Zealand Pharma major shareholder announcement: Wellington Management Group LLP

Written by Customer Service on . Posted in Public Companies.

Company announcement – No. 02 / 2020Zealand Pharma major shareholder announcement: Wellington Management Group LLPCopenhagen, February 11, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the receipt of the following major shareholder notification:From January 31, 2020 to February 4, 2020, Wellington Management Group LLP indirectly held a total of DKK 1,816,586 shares and financial instruments with similar economic effect according to section 39(2)(2) of the Danish Capital Markets Act in Zealand (1,801,902 shares corresponding to 4.99% of the total share capital of the Zealand, and 14,684 financial instruments corresponding to 0.04% of the total share capital of the Zealand) and a total of 1,816,586 voting rights (each share carrying one vote) in Zealand corresponding to 5.04% of the total share capital and voting rights of Zealand. Additional details on the financial instruments with similar economic effect is included in the attachments to this announcement.From February 4, 2020, Wellington Management Group LLP indirectly hold a total of DKK 1,827,278 shares and financial instruments with similar economic effect according to section 39(2)(2) of the Danish Capital Markets Act in Zealand (1,812,594 shares corresponding to 5.03% of the total share capital of the Zealand, and 14,684 financial instruments corresponding to 0.04% of the total share capital of the Zealand) and a total of 1,827,278 voting rights (each share carrying one vote) in Zealand corresponding to 5.07% of the total share capital and voting rights of Zealand. Additional details on the financial instruments with similar economic effect is included in the attachments to this announcement.The shares, financial instruments with similar economic effect according to section 39(2)(2) of the Danish Capital Markets Act and voting rights in Zealand are directly held by Wellington Management Company LLP and Wellington Management International Ltd.Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.Wellington Management International Ltd is a direct controlled undertaking of Wellington Management Global Holdings, Ltd which, in turn is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.For further information, please contact:Zealand Pharma Investor Relations
+45 50 60 38 00 investors@zealandpharma.comLani Pollworth Morvan, Investor Relations and Communication
lpm@zealandpharma.comAbout Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focuses on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and a pre-clinical license collaboration with Alexion Pharmaceuticals.Zealand is based in Søborg, Denmark. For further information about the company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  Attachments02-20_0211_ZealandPharma_major shareholder announcementZealand Pharma AS Filing 31-Jan-2020 Wellington Management Group LLPZealand Pharma AS Filing 04-Feb-2020 Wellington Management Group LLP

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.